ArticleProceedings. Biological sciences2009
Protection of Salmonella by ampicillin-resistant Escherichia coli in the presence of otherwise lethal drug concentrations.
Article in Proceedings. Biological sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 81 citations in OpenAlex.
- Microbiome ecology and antibiotic treatment failure: resistance spread, microbial competition and community engineering.Microbial genomics · 2026Review
- Microbial interactions in facilitating antibiotic activity and resistance evolution.Applied and environmental microbiology · 2026Review
- Cooperative antibiotic resistance in bacteria: beyond biofilms.Frontiers in microbiology · 2026Review
- Higher levels of antibiotic resistance are less competitive: the hidden ecological cost of no-metabolic cost resistance.bioRxiv : the preprint server for biology · 2025Article
- Contributions of β-lactamase substrate specificity and outer membrane permeability to the antibiotic sheltering of β-lactam-susceptible bacteria.RSC chemical biology · 2025Article
- Article
- Cooperative resistance varies among β-lactamases in E. coli, with some enabling cross-protection and sustained extracellular activity.Communications biology · 2025Article
- Towards unraveling antimicrobial resistance dynamics: a longitudinal exploration of rectal swab metagenomes.BMC microbiology · 2025Article
- Spatial population dynamics of bacterial colonies with social antibiotic resistance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Pharmacodynamics of interspecies interactions in polymicrobial infections.NPJ biofilms and microbiomes · 2025Article
- Stenotrophomonas maltophilia impedes Bacillus biocontrol of tomato wilt disease by degrading its lipopeptide antibiotics.The ISME journal · 2025Article
- Optogenetic patterning generates multi-strain biofilms with spatially distributed antibiotic resistance.Nature communications · 2024Article
- Private benefit of β-lactamase dictates selection dynamics of combination antibiotic treatment.Nature communications · 2024Article
- When does antimicrobial resistance increase bacterial fitness? Effects of dosing, social interactions, and frequency dependence on the benefits of AmpCEvolution letters · 2024Article
- Plasmid-free cheater cells commonly evolve during laboratory growth.Applied and environmental microbiology · 2024Article
- Ecological dependencies and the illusion of cooperation in microbial communities.Microbiology (Reading, England) · 2024Article
- Antibiotic-degrading resistance changes bacterial community structure via species-specific responses.The ISME journal · 2023Article
- Antibiotic resistance in bacterial communities.Current opinion in microbiology · 2023Review
- Cooperative antibiotic resistance facilitates horizontal gene transfer.The ISME journal · 2023Article
- Gut microbiota interspecies interactions shape the response of Clostridioides difficile to clinically relevant antibiotics.PLoS biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Microbial systems have become the preferred testing grounds for experimental work on the evolution of traits that benefit other group members. This work, based on conceptual and theoretical models of frequency-dependent selection within populations, has proven fruitful in terms of understanding the dynamics of group beneficial or 'public goods' traits within species. Here, we expand the scope of microbial work on the evolution of group-beneficial traits to the case of multi-species communities, particularly those that affect human health. We examined whether beta-lactamase-producing Escherichia coli could protect ampicillin-sensitive cohorts of other species, particularly species that could cause human disease. Both beta-lactamase-secreting E. coli and, surprisingly, those engineered to retain it, allowed for survival of a large number of ampicillin-sensitive cohorts of Salmonella enterica serovar Typhimurium, including both laboratory and clinical isolates. The Salmonella survivors, however, remained sensitive to ampicillin when re-plated onto solid medium and there was no evidence of gene transfer. Salmonella survival did not even require direct physical contact with the resistant E. coli. The observed phenomenon appears to involve increased release of beta-lactamase from the E. coli when present with S. enterica. Significantly, these findings imply that resistant E. coli, that are not themselves pathogenic, may be exploited, even when they are normally selfish with respect to other E. coli. Thus, Salmonella can gain protection against antibiotics from E. coli without gene transfer, a phenomenon not previously known. As a consequence, antibiotic-resistant E. coli can play a decisive role in the survival of a species that causes disease and may thereby interfere with successful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.